An investigation for investors in NASDAQ:MRTX shares over potential securities laws violations was announced and NASDAQ:MRTX stockholders should contact the Shareholders Foundation.

San Diego, CA -- (SBWire) -- 06/13/2016 --An investigation on behalf of investors of Mirati Therapeutics, Inc. (NASDAQ:MRTX) shares over potential securities laws violations in connection certain financial statements was announced.

Investors who purchased shares of Mirati Therapeutics, Inc. (NASDAQ:MRTX), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.

The investigation by a law firm focuses on whether a series of statements regarding Mirati Therapeutics' business, its prospects and its operations were materially false and misleading at the time they were made.

Shares of Mirati Therapeutics, Inc (NASDAQ:MRTX) reached as high as $43.57 per share in September 2015.

On June 5, 2016, Mirati Therapeutics, Inc. provided an update on three current ongoing clinical programs in patients with non-small cell lung cancer (NSCLC) and other solid tumors.

Shares of Mirati Therapeutics, Inc. (NASDAQ:MRTX) declined from as high as $19.25 per share on June 3, 2016, to as low as $9.11 per share on June 8, 2016.

On June 9, 2016, NASDAQ: MRTX shares closed at $9.62 per share.

Those who purchased shares of Mirati Therapeutics, Inc. have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com